Moderna Insider Trading Reports

Moderna (NASDAQ: MRNA) insider trading reports (Form 4)

CEO Stephan Bancel

Key officers and directors: Sell, Sell, Sell!

https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0001682852

Owner Filings Transaction Date Type of Owner
Bancel Stephane 0001443340 2020-07-29 director, officer: Chief Executive Officer
Zaks Tal Zvi 0001690927 2020-07-27 officer: Chief Medical Officer
Hoge Stephen 0001760669 2020-07-23 officer: President
NABEL ELIZABETH G 0001619929 2020-07-15 director
Tallett Elizabeth E 0001192460 2020-07-01 director
HENDERSON LORI M. 0001221127 2020-06-18 officer: General Counsel and Secretary
Meline David W 0001444612 2020-06-08 officer: Chief Financial Officer
Kim Lorence H. 0001643746 2020-06-02 officer: Chief Financial Officer
AFEYAN NOUBAR 0001222012 2020-05-21 director, 10 percent owner
Flagship Ventures Fund IV, L.P. 0001503559 2020-05-21 10 percent owner
Flagship Ventures Fund IV General Partner LLC 0001508051 2020-05-21 director, 10 percent owner
Flagship Ventures Fund IV-Rx, L.P. 0001590973 2020-05-21 10 percent owner
Andres Juan 0001760670 2020-05-13 officer: See remarks
SAGAN PAUL 0001035440 2020-04-29 director
LANGER ROBERT 0001239757 2020-04-29 director
Nader Francois 0001365343 2020-04-29 director
Horning Sandra 0001638709 2020-04-29 director
Slaoui Moncef 0001712369 2020-04-29 director
Berenson Stephen 0001760671 2020-04-29 director
LEE JENNIFER LING 0001675118 2020-03-09 officer: Chief Accounting Officer

moderna 1

Bancel Stephane 0001443340 2020-07-29 director, officer: Chief Executive Officer

https://www.fbcoverup.com/docs/library/2020-07-29-Moderna-Stephane-Bancel-CEO-Sold-$31M-shares-SEC-FORM-4-Jul-29-2020.pdf

stephane bancel

Sold $30,840,614 in shares in her name assigned to Boston Biotech, LLC; Bancel children; OCJA LLC (personal LLC); personally

https://www.crunchbase.com/organization/bb-biotech-ventures

A Zurcih, Switzerland company. Guernsey (offshore) based). Martin Munchbach, Managing Director. Bellevue Asset Management AG.

http://www.bbbiotechventures.com/en/bb-biotech-ventures/

Relationships with Sanofi, Roche, Booz Allen, Genencor, Genzyme, Genentech (Rothschild), Novartis, Ciba-Geigy, Glaxo, Seimens, Hoffman-Roche, Harvard,

. . . . . . .

FYI. Ole Stevie boy has been selling his stock out since Nov. 2019.

No buys. All sells.

https://www.fbcoverup.com/docs/library/2020-08-03-Stephane-Bancel-CEO-Moderna-Inc-Form-D-Insider-Trading-Report-SEC-accessed-Aug-03-2020.pdf

bancel stephane

https://yuzuha.substack.com/p/interview-with-moderna-ceo-stephane

. . . . . . .

Moderna’s latest Proxy Statement Form DEF 14A dated Apr. 10, 2020

Massive Wellcome Trust conflict of interest

Includes numerous conflicting relationships with Goldman Sachs, J.P. Morgan, Wellcome Trust (GlaxoSmithKline – GSK), Harvard, UPenn, Stanford, Merck, Novartis, Sanofi, McKinsey, London School of Economics (notorious promoter of communist ideology), Medtronic, MIT, Dell, Roche, Hoffman-Roche, VMware,

Moderna’s CEO Stephane Bancel and Chief Medical Officer Tal Zaks, MD, Phd have been big stock sellers for a year. Zaks was director of clinical development and translational medice for GLAXOSMITHKLINE (Wellcome Trust – co-owner of the Coronavisur Patent along with the Gates Foundation. THIS CONFLICT IS ALONE IS DISQUALIFYING & FRAUDULENT GIVE GLAXO’S RELATIONSHIP WITH THE PIRBRIGHT INSTITUTE (UK). https://heightzone.com/dr-tal-zaks/

Israeli Tal Zaks – Been only selling his Moderna stock (dumping) since Dec. 2019

This guy is evidently dumping his Moderna shares while he is promoting his supposed COVID vaccine.

That is illegal stock manipulation and should land him and his CEO in jail.

C’mon Bill Barr, do your job.

stephane bancel 2

https://www.sec.gov/Archives/edgar/data/1682852/000119312520103908/d915867ddefa14a.htm

Moderna, Inc. (Filer) CIK0001682852 (see all company filings)

IRS No.: 813467528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38753 | Film No.: 20787049
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences

MANAGEMENT

Executives, non-executive directors and director nominee

The following table sets forth the name, age and position of each of our executives, non-executive directors and director nominee as of March 2, 2020.

Name Age Position
Executives:
Stéphane Bancel (1) 47 Chief Executive Officer and Director
Juan Andres (1) 55 Chief Technical Operations and Quality Officer
Marcello Damiani 50 Chief Digital and Operational Excellence Officer
Tracey Franklin 40 Chief Human Resources Officer
Lori Henderson, J.D. (1) 58 General Counsel and Corporate Secretary
Stephen Hoge, M.D. (1) 44 President
Lorence Kim, M.D. (1) 45 Chief Financial Officer
Tal Zaks, M.D., Ph.D. (1) 54 Chief Medical Officer
Non-Executive Directors:
Noubar B. Afeyan, Ph.D. (4)(5) 57 Chairman, Director
Stephen Berenson (2)(3) 59 Director
Robert Langer, Sc.D. (4) 71 Director
Elizabeth Nabel, M.D. (4)(5) 68 Director
François Nader, M.D.(5) 63 Director
Israel Ruiz(2)(3) 48 Director
Paul Sagan (2)(3) 61 Director
Moncef Slaoui, Ph.D.(5) 60 Director
Director Nominee:
Sandra Horning, M.D. 71 Director nominee
(1) Executive officer
(2) Member of the Audit Committee
(3) Member of the Compensation and Talent Committee
(4) Member of the Nominating and Corporate Governance Committee
(5) Member of the Product Development Committee

These relationships alone should fundamentally disqualify Moderna or any of its INTERLOCKING relationships from any involvement in Coronavirus.

https://www.sec.gov/Archives/edgar/data/1682852/000119312518341958/d611137ds1a.htm

moderna edgar search

.

moderna registration

“Since we nominated our first program in late 2014, we and our strategic collaborators have advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another 3 have open INDs. Our therapeutic and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. We have assembled an exceptional team of approximately 700 employees and have established strategic alliances with leading biopharmaceutical companies, including AstraZeneca, Merck & Co., and Vertex Pharmaceuticals, as well as government-sponsored and private organizations focused on global health initiatives, including Biomedical Advanced Research and Development Authority, or BARDA, Defense Advanced Research Projects Agency, or DARPA, and the Bill & Melinda Gates Foundation. As of September 30, 2018, we have raised over $2.6 billion in total funding from our strategic collaborators and investors, and have cash, cash equivalents, and investments of $1.2 billion. As we unlock the inherent advantages of mRNA, we aim to address as many diseases and impact as many patients as our technology, talent, and capital permit.”

moderna prospectus summary

https://www.sec.gov/Archives/edgar/data/1443340/000112760220022435/xslF345X03/form4.xml

non derivatives securities 1

https://www.sec.gov/Archives/edgar/data/1443340/000112760220022138/xslF345X03/form4.xml

non derivatives securities 2

https://www.sec.gov/Archives/edgar/data/1443340/000112760220022102/xslF345X03/form4.xml

non derivatives securities 3

https://www.sec.gov/Archives/edgar/data/1443340/000112760220022102/xslF345X03/form4.xml

non derivatives securities 4

https://www.sec.gov/Archives/edgar/data/1443340/000112760220021763/xslF345X03/form4.xml

non derivatives securities 5

https://www.sec.gov/Archives/edgar/data/1443340/000112760220021495/xslF345X03/form4.xml

non derivatives securities 6

https://www.sec.gov/Archives/edgar/data/1443340/000112760220021332/xslF345X03/form4.xml

non derivative security 7

https://www.sec.gov/Archives/edgar/data/1443340/000089924320018777/xslF345X03/doc4.xml

non derivatives securities 8

https://www.sec.gov/Archives/edgar/data/1443340/000112760220020892/xslF345X03/form4.xml

non derivatives securities 9

https://www.sec.gov/Archives/edgar/data/1443340/000110465920079182/xslF345X03/a4.xml

non derivatives securities 10

https://www.sec.gov/Archives/edgar/data/1443340/000112760220020206/xslF345X03/form4.xml

non derivatives 11

https://www.sec.gov/Archives/edgar/data/1443340/000112760220019726/xslF345X03/form4.xml

non derivatives 12

https://www.sec.gov/Archives/edgar/data/1443340/000112760220018531/xslF345X03/form4.xml

non derivatives 13

The above screen captures are but a few of 120 SELLS from late 2019 to current

See full list of Stephane Bancel Form 4 insider trading reports

https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001443340

Here’s a full list of the Moderna Insiders

https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0001682852

moderna insiders

moderna stock exchange

See actual chart entries with hot links above

moderna chart

Bancel Stephane 0001443340 2020-07-29 director, officer: Chief Executive Officer

https://www.fbcoverup.com/docs/library/2020-07-29-Moderna-Stephane-Bancel-CEO-Sold-$31M-shares-SEC-FORM-4-Jul-29-2020.pdf

Sold $30,840,614 in shares in her name assigned to Boston Biotech, LLC; Bancel children; OCJA LLC (personal LLC); personally

https://www.crunchbase.com/organization/bb-biotech-ventures

A Zurich, Switzerland company. Guernsey (offshore) based). Martin Munchbach, Managing Director. Bellevue Asset Management AG.

http://www.bbbiotechventures.com/en/bb-biotech-ventures/

bb biotech

Relationships with Sanofi, Roche, Booz Allen, Genencor, Genzyme, Genentech (Rothschild), Novartis, Ciba-Geigy, Glaxo, Seimens, Hoffman-Roche, Harvard,

.

Executives

Stéphane Bancel has served as our Chief Executive Officer since October 2011 and a member of our board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA (Euronext: BIM). From July 2000 to March 2006, he served in various roles at Eli Lilly and Company (NYSE: LLY), including as Managing Director, Belgium, and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Eli Lilly and Company, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux. Mr. Bancel currently serves on the board of directors of Qiagen N.V. (NYSE: QGEN) and previously served on the boards of directors of BG Medicine, Inc. (OTCMKTS: BGMD) and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School. We believe that Mr. Bancel is qualified to serve on our board of directors because of his extensive leadership experience in the healthcare industry and experience as a director of public and private companies.

Juan Andres joined the Company in August 2017, and has served as our Chief Technical Operations and Quality Officer since August 2018. Before joining the Company, Mr. Andres worked at Novartis AG (NYSE: NVS) from

10

Table of Contents

2005 to 2017, in various roles of increasing responsibility including serving as Global Head, Technical Operations (Manufacturing and Supply Chain), Global Head of Quality, and Global Head of Technical Research and Development. From 1987 to 1996, Mr. Andres served in various manufacturing, production, and quality roles at Eli Lilly and Company (NYSE: LLY), including as Vice President, Pharmaceutical Manufacturing. Mr. Andes has served as a member of the board of directors of Evelo Biosciences, Inc. (Nasdaq: EVLO) since December 2019, and of Avantor, Inc. (NYSE: AVTR), since September 2019. Mr. Andres obtained a degree in pharmacy at the Universidad de Alcalá in Spain.

Marcello Damiani joined the Company in May 2015, and has served as our Chief Digital and Operational Excellence Officer since September 2018. From 2009 to 2015, Mr. Damiani held senior roles at bioMérieux (Euronext: BIM), including Senior Vice President and Group Chief Information Officer. Mr. Damiani holds an M.S. degree in Information Systems Architecture from the University of Toulouse, France and completed an international Executive M.B.A. program through TRIUM, an alliance of the London School of Economics, the NYU Stern Business School, and the HEC Paris School of Management, France.

Tracey Franklin has served as our Chief Human Resources Officer since October 2019. From 2004 to October 2019, Ms. Franklin held positions of increasing responsibility at Merck & Co., Inc., including most recently Vice President, HR Chief Talent and Strategy Officer. Ms. Franklin holds a B.A. in communication arts and sciences from Pennsylvania State University and a Masters in industrial and organizational psychology from Fairleigh Dickinson University.

Lori Henderson, J.D., has served as our General Counsel and Corporate Secretary since April 2018. From 2011 to 2018, Ms. Henderson served at Albany Molecular Research Inc. (Nasdaq: AMRI) first as Vice President, General Counsel and Corporate Secretary until 2014 and then as Senior Vice President, General Counsel and Head of Business Development. Prior to her time at AMRI, Ms. Henderson worked as a corporate attorney at Goodwin Procter LLP and as a General Counsel at other corporations. She received her J.D. from the George Washington University Law School and her B.A. in Business and Economics from Gordon College.

Stephen Hoge, M.D., joined the Company in January 2013 and has served as our President since February 2015. From 2010 to 2012, Dr. Hoge was a Partner at McKinsey & Company and a leader in the firm’s healthcare practice. From 2005 to 2010, he served in roles of increasing responsibility at McKinsey & Company. From 2004 to 2005, Dr. Hoge was a resident physician at New York University/Bellevue Hospital. Dr. Hoge has served on the board of directors of Axcella Health, Inc. (Nasdaq: AXLA). He received an M.D. from the University of California, San Francisco and a B.A. in neuroscience from Amherst College.

Lorence Kim, M.D., has served as our Chief Financial Officer since April 2014. From July 2000 to April 2014, Dr. Kim held a number of positions at Goldman, Sachs & Co., most recently as a Managing Director and co-head of biotechnology investment banking. Dr. Kim has served on the board of directors of Seres Therapeutics, Inc. (Nasdaq: MCRB) since 2014. He received an A.B. in Biochemical Sciences from Harvard University, an M.B.A. in Healthcare Management from the Wharton School of the University of Pennsylvania, and an M.D. from the University of Pennsylvania School of Medicine.

Tal Zaks, M.D., Ph.D., has served as our Chief Medical Officer since March 2015. Prior to joining the Company, Dr. Zaks served in senior development positions at Sanofi (NYSE: SNY) from 2010 to 2015, including Senior Vice President and Head of Global Oncology. From July 2008 to May 2010, he served as Vice President of Clinical Research, Oncology at Cephalon. Prior to this, Dr. Zaks spent four years at GlaxoSmithKline (NYSE: GSK) as Director, Clinical Development and Translational Medicine and three years at the National Cancer Institute as a Postdoctoral Fellow. He is currently an Associate Professor of Medicine at the University of Pennsylvania and serves on the board of directors of Adaptimmune Therapeutics plc (Nasdaq: ADAP). Dr. Zaks received his M.D. and Ph.D. from the Ben Gurion University in Israel and conducted post-doctoral research at the U.S. National Institutes of Health. He completed his clinical training in internal medicine at Temple University Hospital followed by a fellowship in medical oncology at the University of Pennsylvania.

11

Table of Contents

Non-executive directors

Noubar B. Afeyan, Ph.D., is a co-founder and has served on our board of directors since incorporation, and has served as a chairman of our board of directors since February 2012. In 1999, Dr. Afeyan founded Flagship Pioneering and serves as its Senior Managing Partner and Chief Executive Officer. Since April 2013, Dr. Afeyan has served on the board of directors of Rubius Therapeutics, Inc. (Nasdaq: RUBY) and since October 2010, on the board of Seres Therapeutics, Inc. (Nasdaq: MCRB). He currently serves on the boards of numerous privately held companies, and has previously served on the boards of numerous privately and publicly held companies, including Evelo Biosciences, Inc. (Nasdaq: EVLO), Kaleido Biosciences, Inc. (Nasdaq: KLDO) and BG Medicine, Inc (OTCMKTS: BGMD). He received a Ph.D. in biochemical engineering from the Massachusetts Institute of Technology (“MIT”) and a B.S. in chemical engineering from McGill University. Dr. Afeyan is currently a visiting lecturer of business administration at Harvard Business School and was previously a senior lecturer at MIT’s Sloan School of Management where he taught courses on technology-entrepreneurship, innovation, and leadership. We believe that Dr. Afeyan’s significant experience co-founding, leading, and investing in numerous biotechnology companies make him qualified to serve on our board of directors.

Stephen Berenson has served as a member of our board of directors since October 2017. Mr. Berenson is a Managing Partner at Flagship Pioneering. Prior to that, Mr. Berenson spent 33 years as an investment banker at J.P. Morgan. During his last twelve years at J.P. Morgan, Mr. Berenson was Vice Chairman of Investment Banking and focused on providing high-touch strategic advice and complex transaction execution to leading companies across all industries globally. He was co-founder of J.P. Morgan’s Global Strategic Advisory Council and co-founder of the firm’s Board Initiative. Mr. Berenson also serves as Chairman of the board of directors of Seres Therapeutics, Inc. (Nasdaq: MCRB) and on the board of directors of CiBO Technologies, Inc. Mr. Berenson received an S.B. in mathematics from MIT. We believe that Mr. Berenson is qualified to serve on our board of directors because of his experience in the banking and investment industries.

Robert Langer, Sc.D., has served as a member of our board of directors since December 2010. Dr. Langer has been an Institute Professor at MIT since 2005, and prior to that was a Professor at MIT beginning in 1977. Dr. Langer currently serves on the board of directors of Rubius Therapeutics, Inc. (Nasdaq: RUBY), Kala Pharmaceuticals, Inc. (Nasdaq: KALA), and the UK public company Puretech Health plc (LON: PRTC), and previously served on the board of directors of Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), Wyeth (NYSE: WYE), Fibrocell Science, Inc. (Nasdaq: FCSC) and Millipore Corporation (acquired by Merck KGaA in 2010). Dr. Langer also served as a member of the Science Board to the U.S. Food and Drug Administration from 1995 to 2002, including his service as chairman from 1999 to 2002. Dr. Langer received his B.S. from Cornell University and his Sc.D. from MIT, both in Chemical Engineering. We believe that Dr. Langer is qualified to serve on our board of directors because of his pioneering academic work, extensive medical and scientific knowledge and experience, and his previous service on public company boards of directors.

Elizabeth Nabel, M.D., has served as a member of our board of directors since December 2015. Dr. Nabel has served as President of Harvard University-affiliated Brigham Health, which includes Brigham and Women’s Hospital, Brigham and Women’s Faulkner Hospital, and the Brigham and Women’s Physician Organization, since 2010. Dr. Nabel has also been a Professor of Medicine at Harvard Medical School since 2010. Prior to that, Dr. Nabel held a variety of roles, including Director, at the National Heart, Lung and Blood Institute at the National Institutes of Health, a federal agency funding research, training and education programs to promote the prevention and treatment of heart, lung and blood diseases, from 1999 to 2009. She is an elected member of the National Academy of Medicine of the National Academy of Sciences. Dr. Nabel currently serves on the board of directors of Medtronic plc (NYSE: MDT) and as a trustee of Tekla Capital Management LLC. We believe that Dr. Nabel is qualified to serve on our board of directors because of her extensive experience in the health care field, including senior positions with a number of research universities and organizations.

François Nader, M.D., has served as a member of our board of directors since December 2019. Dr. Nader currently serves as Chairman of the board of directors of Acceleron Pharma Inc. (Nasdaq: XLRN), Prevail

12

Table of Contents

Therapeutics Inc. (Nasdaq: PRVL) and Talaris Therapeutics, Inc. He also serves on the board of directors of Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) and as an advisor for SVB Leerink. Dr. Nader is the past Chairman of BioNJ, New Jersey’s biotechnology trade organization, and previously served on the board of the Biotechnology Industry Organization (BIO), NPS Pharmaceuticals (Nasdaq: NPSP), Advanced Accelerator Applications S.A. (Nasdaq: AAAP), Baxalta Inc. (NYSE: BXLT), Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), Trevena Inc. (Nasdaq: TRVN) and Noven Pharmaceuticals Inc. (Nasdaq: NOVN). Dr. Nader earned his French doctorate in medicine from St. Joseph University in Lebanon and a physician executive M.B.A. from the University of Tennessee. We believe that Dr. Nader is qualified to serve on our board of directors because of his experience in integrated healthcare markets and medical and regulatory affairs and his service on numerous boards of directors.

Israel Ruiz has served as a member of our board of directors since February 2017. Mr. Ruiz has been the Executive Vice President and Treasurer at MIT since 2011. In this role, Mr. Ruiz oversees all principal administrative and financial functions of MIT. Prior to his current role, Mr. Ruiz served as the Vice President for Finance for MIT from 2007 to 2011 and as a principal for MIT’s Office of Budget and Financial Planning from 2001 to 2007. He currently serves on the board of directors of FM Global and previously served on the board of directors of Fortive Corporation (NYSE: FTV). Mr. Ruiz received a degree in industrial and mechanical engineering from the Polytechnic University of Catalonia and a master’s degree from the MIT Sloan School of Management. We believe that Mr. Ruiz is qualified to serve on our board of directors because of his deep financial and accounting experience as the chief financial officer of MIT.

Paul Sagan has served as a member of our board of directors since June 2018. Mr. Sagan has been a Managing Director at General Catalyst Partners, a venture capital firm, since January 2018, and previously served as an Executive In Residence (XIR) since January 2014. From April 2005 to January 2013, Mr. Sagan served as Chief Executive Officer at Akamai Technologies, Inc. (Nasdaq: AKAM) and was President from May 1999 to September 2010 and from October 2011 to January 2013. He was also a director of Akamai Technologies until 2019. Mr. Sagan currently serves on the board of directors of VMware, Inc. (NYSE: VMW) and was a director of EMC from December 2007 until the acquisition by Dell, Inc. in September 2016. Mr. Sagan received his B.S. from the Medill School of Journalism at Northwestern University. We believe that Mr. Sagan is qualified to serve on our board of directors because of his experience and leadership both in the technology and venture capital fields.

Moncef Slaoui, Ph.D., has served as a member of our board of directors since July 2017. Dr. Slaoui joined GlaxoSmithKline Plc (NYSE: GSK) (“GSK”) in 1988, where he engineered the development of a robust vaccines pipeline. He then led worldwide business development for pharmaceutical products before his appointment to lead research and development in 2006. He assumed overall responsibility for GSK’s Oncology Business in 2010, for GSK Vaccines in 2011, and for all Global Franchises in 2012. Dr. Slaoui is Chairman of the board of directors of Galvani Bioelectronics, a company launched in November 2016 that GSK jointly owns with Verily Life Sciences. Dr. Slaoui has advised the U.S. President’s Council of Advisors on Science and Technology, was a member of the Board of the Agency for Science, Technology, & Research until January 2011, the PhRMA Foundation Board from 2008 to 2016, and the Advisory Committee to the Director of the National Institutes of Health from 2011 to 2016. Dr. Slaoui previously served on the board of directors of Intellia Therapeutics Inc. (Nasdaq: NTLA). Dr. Slaoui is also a former Professor of Immunology at the University of Mons, Belgium. Dr. Slaoui received a Ph.D. in Molecular Biology and Immunology from Université Libre de Bruxelles. We believe that Dr. Slaoui is qualified to serve on our board of directors because of his vast experience in the pharmaceutical industry and various leadership positions.

Director nominee

Sandra Horning, M.D., is nominated to serve as a Class II director on our board. Dr. Horning was the Chief Medical Officer and Global Head of Product Development of Roche, Inc., from 2009 until her retirement in 2019. Prior to Roche, Dr. Horning spent 25 years as a practicing oncologist, investigator and tenured professor at the Stanford University School of Medicine, where she remains a professor of medicine emerita. From 2005 to

13

Table of Contents

2006, she served as President of the American Society of Clinical Oncology. From 2015 to 2018, Dr. Horning served on the Foundation Medicine Board of Directors. She currently serves as an advisor to EQRx, Inc. Dr. Horning received her M.D. from the University of Iowa School of Medicine and completed her post-graduate fellowship in Oncology and Cancer Biology at Stanford University. We believe that Dr. Horning is qualified to serve on our board of directors because of her significant experience in the field of oncology and her product development leadership experience.

. . . . . . .

This financial disclosure is from Moderna’s Initial Public Offering (S-1) disclosure filed on Nov. 09, 2018.

It shows the interlocking and seditious relationships that disqualify ALL of these actors in the current Coronavirus Scam-demic… Gates Foundation, DARPA, BARDA, Merck, AstraZeneca (ICI, British government, Queen’s Golden Share) and Moderna’s Israeli chief medical officer Tal Zaks who was a clinical director at GlaxoSmithKline (Wellcome Trust, agent of the Pilgrims Society and the Queen’s Privy Council)

https://www.sec.gov/Archives/edgar/data/1682852/000119312518323562/d577473ds1.htm

.

Breaking News: Just leaked Jan. 08, 1981 PM Margaret Thatcher 10 Downing Street letter shows seditious use of the American Pilgrims Society and Georgetown as instruments of British foreign policy and propaganda

Francis Richards, Foreign and Commonwealth Office (FCO). (Jan. 08, 1981). Prime Minister Margaret Thatcher’s Visit to the United States: Georgetown University, U.S. Pilgrims Society, including Donovan Award. 10 Downing Street.

This is yet more proof that the U.S. members of the Anglo-American (British) Pilgrims Society are all traitors to the United States and its sovereignty. Remember, Pilgrims vice presidents Henry Kissinger and Paul Volcker (2007-2008) were chief orchestrators of the 2008 bank “bailout” scam to enable Pilgrims banks to further consolidate their global power for the takeover of the American Republic.

See: AFI. (Jul. 28, 2020). The Anglo-American (British) Pilgrims Society and its CFR minions used the Marshall Plan, shrouded in anti-communism, to seize control of global banking using Nazi & Japanese stolen gold. Americans for Innovation.

thatcher 1

thatcher 2

thatcher 3

.

Important Message to Americans from Yugoslavian Patriot

.

Let us pray for President Trump. His success in defeating the Evil Empire is important to every human being on the planet. The Rothschild-British Imperial Empire must be destroyed if humanity is to ever live in peace and prosperity.

mcnaughton trump prays with leaders

The world is counting on us, Patriots. Step up and do your part to resist the petty tyrants in your community and state.

communists pepe election

.

vote trump 2020

.

.

Whitmer calls for a federal mask mandate

michiganFor our fellow Michigan warriors:

We will be bundling important news from Michigan as it relates to the ongoing Information War being waged on Americans by the Pilgrims Society. Under the headlines are links to articles that explain in detail.

White House: Federal law enforcement officers coming to Detroit

“In recent weeks there has been a radical movement to defend, dismantle and dissolve our police department,” Trump said at a Wednesday White House event, blaming the movement for “a shocking explosion of shootings, killings, murders and heinous crimes of violence.”

Whitmer calls for a federal mask mandate

Parents, if you do not take control of your children’s education, their 2020-21 school year is going to look like a Marxist boot camp with testing, vacinations, and indoctrination. Just look what Detroit Public school students are having to go through:

“Detroit Public School officials have five days, starting Wednesday, to test more than 630 summer school students for COVID-19 as a condition of keeping the program operating, a federal judge ruled Tuesday.

Detroit Public Schools Community District attempted to fight the testing requirement, put in place by a Detroit U.S. District Judge Arthur Tarnow, but were able to expand the testing window from two to five days.

Tarnow held a Zoom hearing with attorneys and members of the media over a lawsuit seeking to shut down in-person summer school inside 23 Detroit Public School Community District buildings.” Source

With employment rates lower now as we transition through to our new American economy, parents have an opportunity to stay at home and educate their children and heal the family unit. Home education is great for parents, too, as they can learn things that they missed when they received their own public school indoctrination.

Ann Arbor students likely to start new year online

Secretary of U. S. Indoctrination, Betsy DeVos, a Michigander herself, has an online solution for Ann Arbor students…all packaged and ready to go. State indoctrination in the privacy of your own home! Her Pilgrims Society pals are salivating at the opportunity to sell school systems across America their pricey online curriculum to fill your children’s minds with their anti-American ideologies:

Exposing Betsy DeVos’s Plan for Totalitarian Public Education

 

Homeschooling calculus

State of Michigan details plan to eliminate $2.2-billion budget deficit for 2020

“Cuts of $256 million to K-12 schools, $200 million to colleges and universities, and $97 million in revenue sharing to local governments will all be offset by federal coronavirus funding, under the plan. Also, schools will receive an extra $53 million in hazard pay for teachers and local governments will receive a $53 million boost to cover unexpected costs related to the pandemic.”

soros whitmer pigWill she give up her State Police protection as she cuts police protection from the general public?

Feminazi Governor Whitmer Defunds Police: Cuts $115 Million from State Cops, Replaces Portion with Fed Cash

Then…no surprise…the witch of the mid-west is rewarded for her anti-police decision and positions herself back in the VP race. This is why we give Whitmer so much attention. She has always been a George Soros top-pick for PRESIDENT. She gets in with Biden…then poof the demented Biden is easily removed.

Gretchen the Horrible will rule all 50 states, including yours. People of Michigan: You are first line defense in taking this feminazi out of office. Friday, July 28 the petition party begins!

Important News! Due to Whitmer’s appeal of the petition approval, signing will be delayed until July 29. See full details on our Social Media posts.

Joe Biden Claims Gretchen Whitmer Back Under Consideration for VP

whitmer nurse rached

.

 

Global Genocide Now in Progress

In previous Cat Reports, we have explained the “steps towards genocide.” You all know the first step – identify and classify. It’s the same thing ranchers do before harvesting a herd of animals. This is why governments are requiring you to wear a mask. Science shows us that they do not protect from viruses. It’s about CONTROL. They need a mass of people to fall in line, comply, and not ask questions.

The Uygher people first wore the masks:

uygher wear masks

Then they were forced into home imprisonment, later into concentration camps, surrounded by 5G towers. Of course, they were vaccinated in the process.

vaccinated child

uygher concentration camps

Once inside the camps, the human harvesting begins. First the hair is cut and sold on world markets. Other persons are processed for human organs and blood.

human hair

.

organ harvesting

Once the human masses are chipped, marked, and controlled, they are loaded onto rail cars for further processing. Like a herd of cows and sheep, these humans are headed to the processing plants.

新疆 : 新讲 Xinjiang : a New Explanation

.

Chinese Ambassador Struggles To Explain Shocking Footage Of Handcuffed & Blindfolded Uighurs Loaded Onto Train

.

Global genocide is currently under operation. The Rothschild agents start with the easiest to control populations, like the Uyghers in China, to work out the kinks in the system. While these humans are being harvested TODAY, others like YOU are being prepared for harvest TOMORROW.

First, comes the visual control. It can be a blue scarf (Cambodia), a yellow star (Jews), or a facial covering. The identification step is the deadliest one because you must AGREE to wear it. Once you agree, the genocidists know the rest of the process is easy-peasy. Soon you will be at the FEMA camp, getting ready for processing, too.

This is why you must resist the face mask as though your and your family’s life depends on it – because the next step (microchipping, vaccinations, re-education camps, etc.) may be too much for you to overcome.

mask compliance

.

Couple forced to wear ankle monitors to self-isolate after Kentucky woman tests positive for COVID-19 REMEMBER, IT’S JUST A MASK. IT’S JUST SOCIAL DISTANCING. IT’S JUST AN ANKLE BRACELET, IT’S JUST A VACCINE, IT’S JUST A TRAIN…….IT’S JUST SHOWER.

.

genocide chart

How is your state governor or local dictator preparing you and your family for slaughter?

My State Authorized Mandatory Vaccination…Has Yours?

.

Arizona Gov Is Granted the Right to Forcibly Vaccinate and Indefintely Confine Individuals With Absolutely No Legal Oversight

.

genocide abortion

WWII Secretary of War article triggered Congress to approve the Marshall Plan, NATO

BREAKING HISTORICAL NEWS!!

stimson-henry-lewisIn 1947, Foreign Affairs carried the Henry L. Stimson, WWII Secretary of War article that triggered Congress to approve the Marshall Plan, NATO. See below.

A. The 1947 Foreign Affairs Pitch – We’re in danger if we don’t do this. Same Pilgrims tune, different time.

Henry L. Stimson. (Oct. 01, 1947). The Challenge to Americans. Foreign Affairs.

https://www.fbcoverup.com/docs/library/1947-10-01-The-Challenge-to-Americans-by-Henry-L-Stimson-Foreign-Affairs-Oct-01-1947.pdf

BTW. This Stimson Foreign Affairs file was broken from searching. Not anymore. 😊

Pages from 1947-10-01-The-Challenge-to-Americans-by-Henry-L-Stimson-Foreign-Affairs-Oct-01-1947

B. Danger Fixed, part 1: The Marshall Plan

H.R. 4840, H.R. 4579, Eaton Committee, Pt. 1. (Dec. 17, 1947 to Feb. 12, 1948). United States Foreign Policy For A Post-War Recovery Program (Marshall Plan), U.S., 80th Congress, House, Committee on Foreign Affairs, Hearings, 1948, Vol. 1, 1st and 2nd Sessions, 1268 pgs. GPO. (41.2 MB).

https://www.fbcoverup.com/docs/library/1947-12-17-HR-4840-HR-4579-Eaton-Comm-Pt-1-(Dec-17-1947-to-Feb-12-1948)-US-Frgn-Plcy-For-A-Post-War-Rcvry-Prog-Marshall-Plan-House-Frgn-Affrs-Comm-80th-Cong-1st-and-2nd-Sess-GPO-began-Dec-17-1947.pdf

Marshall-Plan-House-Frgn-Affrs-Comm-80th-Cong-1st-and-2nd-Sess-GPO-began-Dec-17-1947

C. Danger Fixed, part 2: NATO

Tom Connally (TX), Chairman,  (Apr. 27, 1949 to May 03, 1949). Pts. 1-3, Witnesses re. NATO, HEARINGS before the Senate Committee on Foreign Relations, 81st Congress, 1st Session, 81st Congress, 1st Session. GPO. (112 MB).

https://www.fbcoverup.com/docs/library/1949-04-27-to-05-03-Pts-1-3-Witnesses-re-NATO-HEARINGS-before-the-Senate-Committee-on-Foreign-Relations-Sen-Tom-Connally-(TX)-chrmn-81st-Congress-1st-GPO-to-May-03-1949-from%20Apr-27-1949.pdf

Sen-Tom-Connally-(TX)-chrmn-81st-Congress-1st-GPO-to-May-03-1949-from Apr-27-1949

chairman patterson

5. Whew, now we’ll be safe in the hands of the: Pilgrims Society Committee of 300

See the list, starting on p. 682

https://www.fbcoverup.com/docs/library/1947-12-17-HR-4840-HR-4579-Eaton-Comm-Pt-1-(Dec-17-1947-to-Feb-12-1948)-US-Frgn-Plcy-For-A-Post-War-Rcvry-Prog-Marshall-Plan-House-Frgn-Affrs-Comm-80th-Cong-1st-and-2nd-Sess-GPO-began-Dec-17-1947.pdf#page=682

robert patterson

.

hugh moore

.

dean acheson

.

David Dubinsky

.

alger hiss

.

william donovan

.

Allen dulles

.

.

Wilkie Marshall Plan

Editor. (Dec. 01, 1947). Mrs. Willkie To Head Marshall Plan Group, woman’s division. The Indianapolis Star.

https://www.fbcoverup.com/docs/library/1947-12-01-Mrs.-Willkie-To-Head-Marshall-Plan-Group-woman-s-division-The-Indianapolis-Star-Dec-01-1947.pdf

wendell edith wilkie

.

Former Secretary of State Dean Rusk Was a Pilgrims Society War Monger

dean rusk

Michael and Douglas explain how philanthropy has been weaponized against humanity:

.

Raw audio file: https://patriots4truth.files.wordpress.com/2020/07/pilgrim-society-infiltration-in-the-state-department.mp3

 

(David) Dean Rusk KBE Crowdsourcing Records Request

President of the Rockefeller Foundation (1952-1961), right after WWII when Rockefeller and Carnegie were investing heavily in The Tavistock Institute brain washing and mind control media techniques, for use by their fellow Pilgrims Society member David Sarnoff, president of RCA/NBC.

dean rusk 1dean rusk 2

dean rusk 3

David Dean Rusk was the U.S. Secretary of State (1961-1969) during the Kennedy and Johnson administrations. He was involved in the State Department from Korea, through the C.I.A.’s Bay of Pigs debacle and exited with Vietnam and Southeast Asia in flames. Clearly Rusk was one of the most heinous war mongers of the 20th century.

rothschild-nm-victorRusk was a Rhodes Scholar (dominated then by Lord Victor Rothschild, trustee); he was evidently groomed by the Pilgrims Society for his roles, who believed since shortly after its founding that control of the U.S. Secretary of State position was the most effective way to re-absorb America back into a new Imperial Corporatist British Empire.

Rusk won the “Cecil Peace Prize” while at Oxford (1933). Cecil is named for Lord Robert Cecil, a co-founder fo the Pilgrims Society; participant in the First Imperial Press Conference, 1909; co-founder of the Empire Press Union; co-founder of British MI6, MI5 and GC&CS (renamed GCHQ in 1946 when the treasonous “Five Eyes” was created); Imperial War Cabinet propagandist during WWI.

Rusk’s Wikipedia and a UK Independent obituary says he was awarded a KBE (Knight Commander of the British Empire) in 1976, but we cannot find the customary London Gazette announcement of the honor.

CAN YOU HELP US FIND FURTHER OFFICIAL COOROBORATION OF THIS HONOR BY QUEEN ELIZABETH?

https://www.fbcoverup.com/docs/library/2020-07-03-David-DEAN-RUSK-Biography-Wikipedia-accessed-Jul-03-2020.pdf

https://www.fbcoverup.com/docs/library/1994-12-22-David-DEAN-RUSK-Obituary-by-Godfrey-Hodgson-The-Independent-UK-Dec-22-1994.pdf

dean rusk knighthood

Dean Rusk took over the Rockefeller Foundation financing of the Tavistock Institute after WWII… ten years before he became Kennedy’s Secretary of State! By then, no doubt, Tavistock brain washing had been thoroughly been implemented by David Sarnoff at RCA and NBC.—more evidence of Pilgrims Society plans for a “new world order” with their corporation governing the planet

https://www.fbcoverup.com/docs/library/2015-From-the-Science-of-Selection-to-Psychologising-Civvy-Street-The-Tavistock-Group-1939-1948-by-Alice-Victoria-White-Univ-of-Kent-(UK)-Academic-Repository-2015.pdf

https://www.fbcoverup.com/docs/library/2005-The-Tavistock-Institute-of-Human-Relations-by-John-Coleman-Family-Guardian-2005.pdf

https://www.fbcoverup.com/docs/library/2018-12-23-John-Rawlings-Rees-Tavistock-Institute-Rockefeller-Wikipedia-accessed-Dec-23-2018.pdf

rockefeller 1rockefeller 2rockefeller 3rockefeller 4Rockefeller 5

Vance Packard’s book The Hidden Persuaders, about media manipulation in the 1950s, hidden persuaderssold more than a million copies.

In The Hidden Persuaders, first published in 1957, Packard explored advertisers’ use of consumer motivational research and other psychological techniques, including depth psychology and subliminal tactics, to manipulate expectations and induce desire for products, particularly in the American postwar era. He identified eight “compelling needs” that advertisers promise products will fulfill.

.

.

rockefeller 6rockefeller 7

final solution rothschild prison planet

Patent Application #060606: Has the Mark of the Beast been patented?

Michael and Tyla give a brief overview of Patent Application 060606 in the audio strip below.

Raw audio file: https://patriots4truth.files.wordpress.com/2020/06/patent-application-0606060.mp3

Application Number 060606—it’s not a patent, yet. The parties are still preparing the claims ground for the big kill, on both sides.

It is not available on the USPTO search (which is probably illegal suppression of information of a notoriously public interest), but is available through the PUBLIC PAIR.

Notice to Patriots: This may be a dog whistle to distract from the implementation of 5G that this kind of technology needs to work.

Right now, this patent is an application that is getting some pushback at the World Patent Office. Remember, the U.S. Patent Office is run by British SERCO, so one thing is assured. These plans are demonic, not matter who is awarded the patent, or even if it is awarded (they can still be implementing it).

Novice patent application readers should understand something about the patenting process. If you intended to claim a patent monopoly on your invention, you must first specify all the ways you think your invention can be used. If you leaving something out, inadvertent or intentionally, you cannot claim the patent protection later. This is probably why the U.S. Patent Office is hiding much of Microsoft’s detail submissions of prior art. They do not want you to discover their heinous plans for you and me.

U.S. (SERCO UK) Pat. App. No. 16/138,518 Abramson et al. (Wrapper Accessed Jun. 30, 2020). Miscellaneous Internal Document, Jun. 12, 2020, CRYPTOCURRENCY SYSTEM USING BODY ACTIVITY DATA, filed Sep. 21, 2018, assigned to Microsoft Technology Licensing, LLC. USPTO (British SERCO).

The WIPO patent examiner claims that this document (above) invalidates Microsoft’s claim. Microsoft claims that it does not.

This game reveals the Pilgrims Society game: give your opponents yesterday’s invention while you pursue a greater one to fight them with.

With this conflict now fabricated, the U.S. and Russian governments can each justify spending billions of not trillions of dollars of war-funds to “protect” each from the other. The same set of bankers, namely the Rothschilds – J.P. Morgan Chase and their down line, can then fund both sides of this weaponry build up. This game is up.

The resumes of the Russians involved with this brochure just submitted by Microsoft on Jun. 12, 2020 (10 days ago) reveals the game. Russia claims to have it. Microsoft will eventually get awarded a different claim for even more advanced stuff.

This “patent” invention fakery is now exposed.

Bilgili

Ferring Pharmaceuticals is owned by Blackstone Group (C.I.A.)

Marycevberkovichnikiovitch

The listed World Intellectual Patent Office (WIPO) Inventors for this 1. WO2020060606 – CRYPTOCURRENCY SYSTEM USING BODY ACTIVITY DATA

JOHNSON, Joseph Edwin, JR. works and files patents for Amazon Technologies (this shows how closely Microsoft-CIA and Amazon-CIA conspire

joseph edwin Johnson

PAT. NO. Title
10,275,819 Reducing incompatible pairings
10,083,357 Image-based item location identification
10,002,377 Infrared driven item recommendations
9,965,793 Item selection based on dimensional criteria
9,711,985 Techniques for mobile device charging using robotic devices
9,665,960 Image-based item location identification
9,492,922 Techniques for mobile device charging using robotic devices

ABRAMSON, Dustin works and files patents for Microsoft

joseph edwin johnson 2

PAT. NO. Title
10,581,765 Conversation bot discovery and response fusion
10,535,344 Conversational system user experience
10,468,050 Voice synthesized participatory rhyming chat bot
10,250,532 Systems and methods for a personality consistent chat bot

Fu, Derrick IS NOT LISTED IN THE US PATENT OFFICE as having ever filed for anything at the USPTO – Now he is claiming an invention to run your body, remotely.

This is just obscene in the games these Microsoft-CIA-IBM-Siemens-WorldBank-Ferring-Blackstone attorneys are playing with our lives and well-being.

Derrick Fu, mystery man.

Worked at IBM, IMS Tools Development Intern (May-Aug 2012) in San Jose

Worked on Microsoft Azure (Aug 2013-Jun 2017)

Worked AI at Microsoft (2017-2019)

Worked Bing Ads (2017-current)

Where’s his crypto experience in his background?

Fu appears to be a ringer.

Derrick Fu

.

mask mark 666